Subhodeep Sarker

About Subhodeep Sarker

Rare “science-to-deal” bridge in global life sciences, I blend deep preclinical research, PE-grade deal work, and multilingual, multi-region experience into a differentiated strategic asset for life sciences clients and investors. End to end science–to–investment value architect- Strategic impact: I can sit with scientists, PE deal teams, and operating partners in the same room and make the science, the model, and the value creation story cohere. My publications track-record (18 peer-reviewed papers in high-impact international journals, Google Scholar Citations>1240; novel analgesics, RNAi PoC, GPCR trafficking) signals to investors and C-suite that I can interrogate scientific risk, novelty, and translational feasibility at a level that many strategy consultants cannot. As a subject matter expert and value architect, I can assess therapeutic platforms, translate them into commercial narratives, and stress-test them through PE-grade diligence lenses in neurology, cardiovascular, and oncology therapeutic areas.2. Platform-level life sciences account and ecosystem builder- Strategic impact: I am a builder of integrated life sciences “franchises” (therapeutic-area platforms, digital health ecosystems, and PE relationships) rather than a single-project subject matter expert, which aligns strongly with how leading life sciences strategy firms structure their specialist partner tracks.3. Multilingual, multi-continent influence amplifier- Strategic impact: As a “global life sciences interlocutor”, I de-risk communication between Western investors, multinational pharma clients, regulators, and local operators. Fluency or high proficiency in English, German, French, Hindi, Konkani, Bengali, and working Mandarin, layered over work experience in the US, EU, and Asia-Pacific, gives me an unusually strong platform to operate in cross-border life sciences deals and transformations. For global PE and pharma clients, my language mix directly maps to key life sciences hubs (DACH, France, US, India, parts of Asia), which is highly prized for cross-border diligence, JV structuring, and post-deal integration where cultural and regulatory nuance matter as much as the numbers.

Experience

1. Manager, Gds Ey-parthenon Value Creation R & d, Growth, and Commercial Strategy Deal Execution

   EY-Parthenon

   Mar 2022 — Present

   In my role as Manager at GDS EY-Parthenon, I execute engagements focused on strategic value creation, cost takeouts, optimizing total shareholder returns, commercial & growth strategy, and deal execution. I provide strategic advice to clients on inorganic growth, acquisitions, and capital restructuring, leading to successful deal closures and client growth. My clientele includes global private equity, life sciences, and healthcare companies across regions.

Education

• Vetmeduni

  University of Veterinary Medicine (Vetmeduni) Vienna Postdoctoral Fellowship, RNAi Therapeutics

  2013 — 2017

• University of Sydney

  Erwin Schrödinger Fellowship (Principal Investigator/ FWF Project Leader), Neuroscience & Photopharmacology

  2017 — 2019

• The Japan Karate Association, Tokyo

  Diploma, SHO (1st) DAN Black Belt in Shotokan Karate-Do

  1990 — 1997

• Indian Institute of Management, Indore

  Master of Business Administration (MBA), General Management

  2020 — 2021

• Goa Board of Secondary and Higher Secondary Education (GBSHSE)

  Pre-Primary, Primary, Secondary, and Higher Secondary Education, Science, Mathematics, Physics, Biology, Chemistry, History, Geography, French, Konkani, Hindi

  1989 — 2003

• Medical University of Vienna

  Doctor of Philosophy (PhD), Molecular Medicine

  2007 — 2010

• Duke University School of Medicine

  Postdoctoral Fellowship, Cardiovascular Pharmacology & Molecular Oncology

  2011 — 2013

• SDA Bocconi

  Advanced Leadership Programme, IIM Indore MBA Term Abroad

  2020 — 2020

• Birla Institute of Technology, Mesra

  Bachelor of Engineering (BE), Bioengineering / Biotechnology

  2003 — 2007